RHYTHM PHARMACEUTICALS (RYTM) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$90.78
+1.3% on the day
-9.4% over 12 months
52-week range $75.82 – $117.62
Share price and insider trades
RYTM closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$41.7M
Insiders buying0
Insiders selling9
RHYTHM PHARMACEUTICALS insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $41.7M of RYTM stock on the open market.
Get emailed when insiders cluster-buy stocks like RYTM
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
RYTM insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $28.8M | 20 |
| Q2 2026 | — | 0 | $4.1M | 2 |
| Q1 2026 | — | 0 | $2.7M | 24 |
| Q4 2025 | — | 0 | $6.1M | 9 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.6×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 RHYTHM PHARMACEUTICALS, INC. insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $41.7M. 53 of 55 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 14SEC | David P MeekerCEO, President | Sell Plan | 30,746252,073 held (−11%) | $102.35 | $3.1M | -11.3% | — |
| Sep 14SEC | David P MeekerCEO, President | Sell Plan | 8,698243,375 held (−3%) | $103.43 | $900K | -12.2% | — |
| Sep 14SEC | David P MeekerCEO, President | Sell Plan | 6,439282,819 held (−2%) | $101.75 | $655K | -10.8% | — |
| Sep 14SEC | David P MeekerCEO, President | Sell Plan | 2,300239,258 held (−1%) | $105.19 | $242K | -13.7% | — |
| Sep 14SEC | David P MeekerCEO, President | Sell Plan | 1,817241,558 held (−1%) | $104.55 | $190K | -13.2% | — |
| Sep 1SEC | Hunter C SmithCFO | Sell Plan | 28,188114,024 held (−20%) | $106.20 | $3.0M | -14.5% | — |
| Sep 1SEC | Hunter C SmithCFO | Sell Plan | 23,072153,726 held (−13%) | $104.59 | $2.4M | -13.2% | — |
| Sep 1SEC | Hunter C SmithCFO | Sell Plan | 11,514142,212 held (−7%) | $105.37 | $1.2M | -13.8% | — |
| Aug 17SEC | Joseph ShulmanChief Technical Officer | Sell Plan | 5,07915,915 held (−24%) | $119.75 | $608K | -24.2% | — |
| Aug 17SEC | Alastair GarfieldChief Scientific Officer | Sell Plan | 3,4003,095 held (−52%) | $118.28 | $402K | -23.2% | — |
| Aug 17SEC | Alastair GarfieldChief Scientific Officer | Sell Plan | 2,0078,051 held (−20%) | $116.11 | $233K | -21.8% | — |
| Aug 17SEC | Alastair GarfieldChief Scientific Officer | Sell Plan | 1,5566,495 held (−19%) | $117.08 | $182K | -22.5% | — |
| Aug 17SEC | Alastair GarfieldChief Scientific Officer | Sell Plan | 8002,295 held (−26%) | $119.17 | $95K | -23.8% | — |
| Aug 14SEC | Jennifer Kayden LeeEvp, Head Of North America | Sell Plan | 75,834 | $117.38 | $8.9M | -22.7% | — |
| Aug 14SEC | Yann MazabraudEvp, Head Of International | Sell Plan | 18,20872,974 held (−20%) | $116.49 | $2.1M | -22.1% | — |
| Aug 14SEC | Yann MazabraudEvp, Head Of International | Sell Plan | 17,31955,655 held (−24%) | $117.47 | $2.0M | -22.7% | — |
| Aug 14SEC | Yann MazabraudEvp, Head Of International | Sell Plan | 14,56891,182 held (−14%) | $115.43 | $1.7M | -21.4% | — |
| Aug 14SEC | Yann MazabraudEvp, Head Of International | Sell Plan | 3,605105,750 held (−3%) | $114.70 | $413K | -20.9% | — |
| Aug 14SEC | Yann MazabraudEvp, Head Of International | Sell Plan | 2,300110,355 held (−2%) | $111.80 | $257K | -18.8% | — |
| Aug 14SEC | Yann MazabraudEvp, Head Of International | Sell Plan | 1,000109,355 held (−1%) | $112.86 | $113K | -19.6% | — |
| Jun 24SEC | Lynn A. TetraultDirector | Sell Plan | 37,0007,000 held (−84%) | $100.32 | $3.7M | -9.5% | — |
| May 19SEC | Christopher Paul GermanCorporate Controller & Cao | Sell | 4,643 | $92.21 | $428K | -1.6% | — |
| Mar 6SEC | Christopher Paul GermanCorporate Controller & Cao | Sell | 5,614160 held (−97%) | $89.56 | $503K | +1.4% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 1,692111,897 held (−1%) | $100.92 | $171K | -10.0% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 1,308113,589 held (−1%) | $100.27 | $131K | -9.5% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 1,200117,266 held (−1%) | $99.42 | $119K | -8.7% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 1,069115,097 held (−1%) | $103.00 | $110K | -11.9% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 900116,166 held (−1%) | $101.70 | $92K | -10.7% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 800111,097 held (−1%) | $102.10 | $82K | -11.1% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 585110,512 held (−1%) | $103.28 | $60K | -12.1% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 200114,897 held (−0%) | $103.84 | $21K | -12.6% | — |
| Feb 19SEC | Hunter C SmithCFO | Sell Plan | 200117,066 held (−0%) | $100.52 | $20K | -9.7% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 2,266120,558 held (−2%) | $98.37 | $223K | -7.7% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 1,913123,624 held (−2%) | $102.66 | $196K | -11.6% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 800118,566 held (−1%) | $98.99 | $79K | -8.3% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 700122,924 held (−1%) | $103.68 | $73K | -12.4% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 400120,158 held (−0%) | $99.44 | $40K | -8.7% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 400119,366 held (−0%) | $97.67 | $39K | -7.1% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 292119,766 held (−0%) | $96.26 | $28K | -5.7% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 100122,824 held (−0%) | $104.76 | $10K | -13.3% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 100120,058 held (−0%) | $100.85 | $10K | -10.0% | — |
| Feb 12SEC | Hunter C SmithCFO | Sell Plan | 100118,466 held (−0%) | $100.10 | $10K | -9.3% | — |
| Feb 6SEC | Hunter C SmithCFO | Sell Plan | 3,381125,537 held (−3%) | $106.06 | $359K | -14.4% | — |
| Feb 6SEC | Hunter C SmithCFO | Sell Plan | 1,500130,665 held (−1%) | $104.74 | $157K | -13.3% | — |
| Feb 6SEC | Hunter C SmithCFO | Sell Plan | 1,000129,665 held (−1%) | $106.60 | $107K | -14.8% | — |
| Feb 6SEC | Hunter C SmithCFO | Sell Plan | 747128,918 held (−1%) | $107.67 | $80K | -15.7% | — |
| Dec 15SEC | Pamela J. CramerChief Human Resources Officer | Sell Plan | 3,35020,814 held (−14%) | $111.00 | $372K | -18.2% | — |
| Nov 24SEC | Pamela J. CramerChief Human Resources Officer | Sell Plan | 3,35020,814 held (−14%) | $105.00 | $352K | -13.5% | — |
| Nov 12SEC | Pamela J. CramerChief Human Resources Officer | Sell Plan | 19,35120,814 held (−48%) | $98.82 | $1.9M | -8.1% | — |
| Nov 12SEC | Pamela J. CramerChief Human Resources Officer | Sell Plan | 3,51520,814 held (−14%) | $100.00 | $352K | -9.2% | — |
| Nov 3SEC | Joseph ShulmanChief Technical Officer | Sell Plan | 9,7488,509 held (−53%) | $115.24 | $1.1M | -21.2% | — |
| Oct 30SEC | Joseph ShulmanChief Technical Officer | Sell Plan | 2,8158,509 held (−25%) | $115.01 | $324K | -21.1% | — |
| Oct 20SEC | Joseph ShulmanChief Technical Officer | Sell Plan | 8,33211,921 held (−41%) | $112.06 | $934K | -19.0% | — |
| Oct 20SEC | Joseph ShulmanChief Technical Officer | Sell Plan | 3,4128,509 held (−29%) | $112.81 | $385K | -19.5% | — |
| Oct 20SEC | Joseph ShulmanChief Technical Officer | Sell Plan | 2,69320,253 held (−12%) | $110.95 | $299K | -18.2% | — |
Insiders at RHYTHM PHARMACEUTICALS, INC.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Jennifer Kayden LeeEvp, Head Of North America | — | $8.9M | Aug 14, 2026 | — |
| Hunter C SmithCFO | — | $8.8M | Sep 1, 2026 | — |
| Yann MazabraudEvp, Head Of International | — | $6.6M | Aug 14, 2026 | — |
| David P MeekerCEO, President | — | $5.1M | Sep 14, 2026 | — |
| Lynn A. TetraultDirector | — | $3.7M | Jun 24, 2026 | — |
| Joseph ShulmanChief Technical Officer | — | $3.7M | Aug 17, 2026 | — |
| Pamela J. CramerChief Human Resources Officer | — | $3.0M | Dec 15, 2025 | — |
| Christopher Paul GermanCorporate Controller & Cao | — | $931K | May 19, 2026 | — |
| Alastair GarfieldChief Scientific Officer | — | $913K | Aug 17, 2026 | — |
RYTM stock: common questions
Are RHYTHM PHARMACEUTICALS, INC. insiders buying RYTM stock?
In the past 12 months, 0 insiders reported open-market purchases of RYTM worth $0.
Are RHYTHM PHARMACEUTICALS, INC. insiders selling RYTM stock?
9 insiders reported sales worth $41.7M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RYTM's 52-week range?
Over the past year RYTM has traded between $75.82 and $117.62. It last closed at $90.78 on Oct 9, 2026.